Non-Small Cell Lung Cancer in Never-Smokers: A New Disease Entity?

被引：3

作者：

Heigener, David F. ^{[1
]}

机构：

[1] Krankenhaus Grosshansdorf, Dept Thorac Oncol, D-22927 Grosshansdorf, Germany

来源：

ONKOLOGIE | 2011年 / 34卷 / 04期

关键词：

Never-smoker; NSCLC; EGFR; EML4-ALK; Targeted therapy; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; PHASE-II TRIAL; ACQUIRED-RESISTANCE; RESIDENTIAL RADON; EGFR MUTATION; SOLID FUELS; RISK; GEFITINIB; GENE;

D O I：

10.1159/000326839

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Non-small cell lung cancer (NSCLC) in never-smokers is an increasing entity. It seems that it has a different pathogenesis, at least in some cases, making it more sensitive to targeted therapies. Two promising targets have so far been identified. This article gives an overview on the biologic background and latest developments in the treatment of this particular entity.

引用

页码：202 / 207

页数：6

共 70 条

[1]

Epidemiology of lung cancer: Looking to the future [J].

Alberg, AJ ;

Brock, MV ;

Samet, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3175-3185

[2]

[Anonymous], ANN ONCOL S8

[3]

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J].

Asahina, H. ;

Yamazaki, K. ;

Kinoshita, I. ;

Sukoh, N. ;

Harada, M. ;

Yokouchi, H. ;

Ishida, T. ;

Ogura, S. ;

Kojima, T. ;

Okamoto, Y. ;

Fujita, Y. ;

Dosaka-Akita, H. ;

Isobe, H. ;

Nishimura, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (08) :998-1004

[4]

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [J].

Bang, Y. ;

Kwak, E. L. ;

Shaw, A. T. ;

Camidge, D. R. ;

Iafrate, A. J. ;

Maki, R. G. ;

Solomon, B. J. ;

Ou, S. I. ;

Salgia, R. ;

Clark, J. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[5]

Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) [J].

Boyer, M. J. ;

Blackhall, F. H. ;

Park, K. ;

Barrios, C. H. ;

Krzakowski, M. J. ;

Taylor, I. ;

Liang, J. Q. ;

Denis, L. J. ;

O'Connell, J. P. ;

Ramalingam, S. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[6]

Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers:: A pooled analysis of two large studies [J].

Brennan, P ;

Buffler, PA ;

Reynolds, P ;

Wu, AH ;

Wichmann, HE ;

Agudo, A ;

Pershagen, G ;

Jöckel, KH ;

Benhamou, S ;

Greenberg, RS ;

Merletti, F ;

Winck, C ;

Fontham, ETH ;

Kreuzer, M ;

Darby, SC ;

Forastiere, F ;

Simonato, L ;

Boffetta, P .

INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (01) :125-131

[7]

HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR INDUCES A VARIETY OF TISSUE-SPECIFIC MORPHOGENIC PROGRAMS IN EPITHELIAL-CELLS [J].

BRINKMANN, V ;

FOROUTAN, H ;

SACHS, M ;

WEIDNER, KM ;

BIRCHMEIER, W .

JOURNAL OF CELL BIOLOGY, 1995, 131 (06) :1573-1586

[8]

BROWNSON RC, 1995, CANCER, V75, P29, DOI 10.1002/1097-0142(19950101)75:1<29::AID-CNCR2820750107>3.0.CO

[9]

2-Q

[10]

Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers [J].

Brownson, RC ;

Alavanja, MCR ;

Caporaso, N ;

Berger, E ;

Chang, JAC .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (02) :256-263

← 1 2 3 4 5 6 7 →